CY2018004I2 - Συνδυαστικη θεραπεια υποκατεστημενης oξαζολιδινονης - Google Patents

Συνδυαστικη θεραπεια υποκατεστημενης oξαζολιδινονης

Info

Publication number: CY2018004I2
Authority: CY; Cyprus
Prior art keywords: combination therapy; substituted oxazolidinone; oxazolidinone; substituted; therapy
Prior art date: 2006-11-02

Application number

CY2018004C

Other languages

English (en)

Other versions

CY2018004I1 (el

Original Assignee

Bayer Intellectual Property Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-02

Filing date

2018-02-15

Publication date

2018-09-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39201619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2018004(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-02-15 Application filed by Bayer Intellectual Property Gmbh filed Critical Bayer Intellectual Property Gmbh

2018-09-05 Publication of CY2018004I2 publication Critical patent/CY2018004I2/el

2018-09-05 Publication of CY2018004I1 publication Critical patent/CY2018004I1/el

Links

IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 title 1
238000002648 combination therapy Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Hematology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CY2018004C 2006-11-02 2018-02-15 Συνδυαστικη θεραπεια υποκατεστημενης oξαζολιδινονης CY2018004I1 (el)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102006051625A DE102006051625A1 (de)	2006-11-02	2006-11-02	Kombinationstherapie substituierter Oxazolidinone
PCT/EP2007/009068 WO2008052671A2 (de)	2006-11-02	2007-10-19	Kombinationstherapie substituierter oxazolidinone

Publications (2)

Publication Number	Publication Date
CY2018004I2 true CY2018004I2 (el)	2018-09-05
CY2018004I1 CY2018004I1 (el)	2018-09-05

Family

ID=39201619

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CY20171101097T CY1119546T1 (el)	2006-11-02	2017-10-20	Συνδυαστικη θεραπεια υποκατεστημενης οξαζολιδινονης
CY2018004C CY2018004I1 (el)	2006-11-02	2018-02-15	Συνδυαστικη θεραπεια υποκατεστημενης oξαζολιδινονης

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CY20171101097T CY1119546T1 (el)	2006-11-02	2017-10-20	Συνδυαστικη θεραπεια υποκατεστημενης οξαζολιδινονης

Country Status (17)

Country	Link
US (2)	US20100120718A1 (el)
EP (1)	EP2099453B1 (el)
JP (1)	JP5379012B2 (el)
KR (2)	KR20150038742A (el)
CN (1)	CN101610767B (el)
CA (1)	CA2668068C (el)
CY (2)	CY1119546T1 (el)
DE (1)	DE102006051625A1 (el)
DK (1)	DK2099453T3 (el)
ES (1)	ES2644489T3 (el)
HU (2)	HUE034869T2 (el)
LT (2)	LT2099453T (el)
LU (1)	LUC00063I2 (el)
PL (1)	PL2099453T3 (el)
PT (1)	PT2099453T (el)
SI (1)	SI2099453T1 (el)
WO (1)	WO2008052671A2 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102006051625A1 (de)	2006-11-02	2008-05-08	Bayer Materialscience Ag	Kombinationstherapie substituierter Oxazolidinone
WO2009018807A1 (de) *	2007-08-06	2009-02-12	Schebo Biotech Ag	Oxazolidinone als faktor xa- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung in der therapie
US9427448B2 (en)	2009-11-11	2016-08-30	The Medicines Company	Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2498731B1 (en) *	2009-11-11	2020-01-22	Chiesi Farmaceutici S.p.A.	Methods of treating or preventing stent thrombosis
US10376532B2 (en)	2009-11-11	2019-08-13	Chiesi Farmaceutici, S.P.A.	Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN104693139B (zh) *	2011-01-07	2017-04-19	浙江九洲药业股份有限公司	一种合成利伐沙班中间体的新工艺
MD4557C1 (ro) *	2011-05-06	2018-10-31	Egis Gyogysszegyar Nyilvanosan Mukodo Reszvenytarsasag	Procedeu de obţinere a rivaroxabanului şi un compus intermediar utilizat în acest procedeu
CN102796091A (zh) *	2011-05-24	2012-11-28	北大方正集团有限公司	取代的噁唑烷酮化合物及其制备方法和应用
EP2838897A1 (en)	2012-04-16	2015-02-25	Ranbaxy Laboratories Limited	Process for the preparation of rivaroxaban and intermediates thereof
CN102746287B (zh) *	2012-06-21	2014-05-28	成都苑东药业有限公司	一种恶唑烷酮化合物及其制备方法
CN104086539A (zh) *	2014-07-17	2014-10-08	天津炜捷制药有限公司	一种利伐沙班的制备方法
CN104402876A (zh) *	2014-11-25	2015-03-11	沈阳药科大学	噁唑烷酮类化合物及其应用
CN104447730B (zh) *	2014-12-05	2017-11-07	广东东阳光药业有限公司	噁唑烷酮类化合物及其在药物中的应用
CN104478866B (zh) *	2014-12-05	2017-07-07	广东东阳光药业有限公司	噁唑烷酮类化合物及其在药物中的应用
CN104447728B (zh) *	2014-12-05	2017-01-04	广东东阳光药业有限公司	噁唑烷酮类化合物及其在药物中的应用
CN104497008B (zh) *	2014-12-09	2016-11-16	广东东阳光药业有限公司	取代噁唑烷酮类化合物及其使用方法和用途
CN104557900A (zh) *	2014-12-23	2015-04-29	中国药科大学	噁唑烷酮类化合物及其制备方法与医药用途
EP3078378B1 (en)	2015-04-08	2020-06-24	Vaiomer	Use of factor xa inhibitors for regulating glycemia
ES3067885T3 (en)	2017-06-23	2026-05-26	Chiesi Farm Spa	Cangrelor for the treatment and/or prevention of shunt or stent thrombosis
US10828310B2 (en) *	2018-02-02	2020-11-10	Bayer Pharma Aktiengesellschaft	Reducing the risk of cardiovascular events
CN110172060A (zh) *	2018-12-27	2019-08-27	苏州二叶制药有限公司	利伐沙班、合成及精制方法
US11608320B2 (en)	2020-02-02	2023-03-21	Kuwait University	Oxazolidinone hydroxamic acid derivatives
WO2021184339A1 (en)	2020-03-20	2021-09-23	Merck Sharp & Dohme Corp.	Oxazolidinone compound and methods of use thereof as an antibacterial agent
CN115894471A (zh) *	2022-11-27	2023-04-04	南京工业大学	一种利伐沙班的合成方法
CN121001727A (zh) *	2023-04-19	2025-11-21	百时美施贵宝公司	米尔维仙(milvexian)于治疗及预防患有心血管或脑血管疾病的患者的血栓病况的用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2811555A (en) *	1955-05-02	1957-10-29	Eastman Kodak Co	Reduction of 2-nitroso-5-diethylaminotoluene
US3279880A (en) *	1965-07-12	1966-10-18	Eastman Kodak Co	Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
LU80081A1 (fr) *	1977-08-26	1979-05-15	Delalande Sa	Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) *	1978-02-10	1978-12-05	E. I. Du Pont De Nemours And Company	5-Halomethyl-3-phenyl-2-oxazolidinones
US4500519A (en) *	1978-11-06	1985-02-19	Choay S.A.	Mucopolysaccharides having biological properties, preparation and method of use
US4327725A (en) *	1980-11-25	1982-05-04	Alza Corporation	Osmotic device with hydrogel driving member
HU190072B (en) *	1983-03-11	1986-08-28	Biogal Gyogyszergyar,Hu	Process for production of medical preparatives with sinergetic influence
US4765989A (en) *	1983-05-11	1988-08-23	Alza Corporation	Osmotic device for administering certain drugs
DE3822650A1 (de) *	1988-07-05	1990-02-01	Boehringer Mannheim Gmbh	Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5254577A (en) *	1988-07-29	1993-10-19	The Du Pont Merck Pharmaceutical Company	Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5654285A (en) *	1991-04-06	1997-08-05	Astra Pharmaceuticals Limited	ADP and ATP analogues, process for making and administration to inhibit ADP-induced platelet aggregation
EP0610265B1 (en) *	1991-11-01	1996-12-27	PHARMACIA & UPJOHN COMPANY	Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
US5349045A (en) *	1993-01-26	1994-09-20	United States Surgical Corporation	Polymer derived from cyclic amide and medical devices manufactured therefrom
ATE181735T1 (de) *	1993-05-01	1999-07-15	Merck Patent Gmbh	Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten
US5688792A (en) *	1994-08-16	1997-11-18	Pharmacia & Upjohn Company	Substituted oxazine and thiazine oxazolidinone antimicrobials
DE4332384A1 (de) *	1993-09-23	1995-03-30	Merck Patent Gmbh	Adhäsionsrezeptor-Antagonisten III
DK0807112T3 (da) *	1995-02-03	2001-12-17	Upjohn Co	Antimikrobiel heteroaromatisk ringsubstitueret phenyloxazolidinon
HRP960159A2 (en) *	1995-04-21	1997-08-31	Bayer Ag	Benzocyclopentane oxazolidinones containing heteroatoms
NZ286920A (en) *	1995-07-03	1997-06-24	Sankyo Co	Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
DE19524765A1 (de) *	1995-07-07	1997-01-09	Boehringer Mannheim Gmbh	Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19601264A1 (de) *	1996-01-16	1997-07-17	Bayer Ag	Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19604223A1 (de) *	1996-02-06	1997-08-07	Bayer Ag	Neue substituierte Oxazolidinone
HRP970049A2 (en) *	1996-02-06	1998-04-30	Bayer Ag	New heteroaryl oxazolidinones
FR2744918B1 (fr)	1996-02-19	1998-05-07	Sanofi Sa	Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
DE19747261A1 (de) *	1997-10-25	1999-04-29	Bayer Ag	Osmotisches Arzneimittelfreisetzungssystem
US20010029351A1 (en) *	1998-04-16	2001-10-11	Robert Falotico	Drug combinations and delivery devices for the prevention and treatment of vascular disease
ES2182521T3 (es) *	1998-05-18	2003-03-01	Upjohn Co	Mejoramiento de la actividad de agentes antibacterianos de oxazolidinona mediante derivados de arginina.
DE19842753A1 (de) *	1998-09-18	2000-03-23	Bayer Ag	Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
DE19962924A1 (de) *	1999-12-24	2001-07-05	Bayer Ag	Substituierte Oxazolidinone und ihre Verwendung
CN1413218A (zh) *	1999-12-28	2003-04-23	味之素株式会社	天冬甜素衍生物的结晶
DE10105989A1 (de) *	2001-02-09	2002-08-14	Bayer Ag	Substituierte Oxazolidinone und ihre Verwendung
DE10110438A1 (de) *	2001-03-05	2002-09-19	Bayer Ag	Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110747A1 (de) *	2001-03-07	2002-09-12	Bayer Ag	Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10110754A1 (de) *	2001-03-07	2002-09-19	Bayer Ag	Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115945A1 (de) *	2001-03-30	2002-10-02	Bayer Ag	Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115922A1 (de) *	2001-03-30	2002-10-10	Bayer Ag	Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10129725A1 (de) *	2001-06-20	2003-01-02	Bayer Ag	Kombinationstherapie substituierter Oxazolidinone
AU2002341693B2 (en)	2001-09-21	2008-05-29	Bristol-Myers Squibb Holdings Ireland Unlimited Company	Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
DE10152460A1 (de) *	2001-10-24	2003-05-08	Bayer Ag	Stents
DE10238113A1 (de) *	2001-12-11	2003-06-18	Bayer Ag	Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
US20030161882A1 (en) *	2002-02-01	2003-08-28	Waterman Kenneth C.	Osmotic delivery system
US20040067995A1 (en)	2002-10-02	2004-04-08	Wong Pancras C.	Novel combination of a factor Xa inhibitor and clopidogrel
DE10300111A1 (de) *	2003-01-07	2004-07-15	Bayer Healthcare Ag	Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) *	2003-11-27	2005-06-23	Bayer Healthcare Ag	Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004002044A1 (de) *	2004-01-15	2005-08-04	Bayer Healthcare Ag	Herstellverfahren
JP2008517974A (ja)	2004-10-25	2008-05-29	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	抗血栓薬と併用しての血栓塞栓性疾患の治療および予防のためのジピリダモールの使用
DE102004062475A1 (de) *	2004-12-24	2006-07-06	Bayer Healthcare Ag	Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
US20060222640A1 (en)	2005-03-29	2006-10-05	Boehringer Ingelheim International Gmbh	New pharmaceutical compositions for treatment of thrombosis
DE102006051625A1 (de)	2006-11-02	2008-05-08	Bayer Materialscience Ag	Kombinationstherapie substituierter Oxazolidinone

2006
- 2006-11-02 DE DE102006051625A patent/DE102006051625A1/de not_active Withdrawn
2007
- 2007-10-19 ES ES07819133.5T patent/ES2644489T3/es active Active
- 2007-10-19 SI SI200731973T patent/SI2099453T1/sl unknown
- 2007-10-19 CA CA2668068A patent/CA2668068C/en active Active
- 2007-10-19 PT PT78191335T patent/PT2099453T/pt unknown
- 2007-10-19 KR KR1020157007667A patent/KR20150038742A/ko not_active Withdrawn
- 2007-10-19 HU HUE07819133A patent/HUE034869T2/en unknown
- 2007-10-19 CN CN2007800491463A patent/CN101610767B/zh not_active Ceased
- 2007-10-19 KR KR1020097008977A patent/KR20090086973A/ko not_active Ceased
- 2007-10-19 LT LTEP07819133.5T patent/LT2099453T/lt unknown
- 2007-10-19 WO PCT/EP2007/009068 patent/WO2008052671A2/de not_active Ceased
- 2007-10-19 DK DK07819133.5T patent/DK2099453T3/da active
- 2007-10-19 EP EP07819133.5A patent/EP2099453B1/de not_active Revoked
- 2007-10-19 JP JP2009535588A patent/JP5379012B2/ja active Active
- 2007-10-19 US US12/513,363 patent/US20100120718A1/en not_active Abandoned
- 2007-10-19 PL PL07819133T patent/PL2099453T3/pl unknown
2016
- 2016-06-23 US US15/190,944 patent/US20160303138A1/en not_active Abandoned
2017
- 2017-10-20 CY CY20171101097T patent/CY1119546T1/el unknown
2018
- 2018-02-06 LU LU00063C patent/LUC00063I2/fr unknown
- 2018-02-08 LT LTPA2018006C patent/LTPA2018006I1/lt unknown
- 2018-02-15 CY CY2018004C patent/CY2018004I1/el unknown
- 2018-02-20 HU HUS1800011C patent/HUS1800011I1/hu unknown

Also Published As

Publication number	Publication date
JP5379012B2 (ja)	2013-12-25
EP2099453A2 (de)	2009-09-16
LUC00063I2 (el)	2018-03-28
PL2099453T3 (pl)	2018-01-31
ES2644489T3 (es)	2017-11-29
HUE034869T2 (en)	2018-03-28
US20160303138A1 (en)	2016-10-20
EP2099453B1 (de)	2017-09-06
LTPA2018006I1 (lt)	2018-02-26
HK1139858A1 (en)	2010-09-30
CN101610767B (zh)	2013-03-13
CN101610767A (zh)	2009-12-23
PT2099453T (pt)	2017-10-31
HUS1800011I1 (hu)	2018-03-28
SI2099453T1 (sl)	2017-11-30
WO2008052671A2 (de)	2008-05-08
WO2008052671A3 (de)	2008-07-03
JP2010508366A (ja)	2010-03-18
CY2018004I1 (el)	2018-09-05
LT2099453T (lt)	2017-11-10
US20100120718A1 (en)	2010-05-13
CA2668068C (en)	2013-12-17
DE102006051625A8 (de)	2008-10-09
DK2099453T3 (da)	2017-11-06
KR20150038742A (ko)	2015-04-08
CA2668068A1 (en)	2008-05-08
CY1119546T1 (el)	2018-03-07
LUC00063I1 (el)	2018-02-12
KR20090086973A (ko)	2009-08-14
DE102006051625A1 (de)	2008-05-08

Publication	Publication Date	Title
CY2018004I1 (el)	2018-09-05	Συνδυαστικη θεραπεια υποκατεστημενης oξαζολιδινονης
DK2035369T3 (da)	2014-10-06	Terapeutiske
BRPI0720347A2 (pt)	2018-11-13	dispositivo implantável
DE602006019782D1 (de)	2011-03-03	Kapselperforationsmodul
DE602007002544D1 (de)	2009-11-05	Nuancierungsmittel
DE602007003893D1 (de)	2010-02-04	Kippambossanordnung
AT504580A3 (de)	2008-07-15	Scan-einrichtung
DE602007000258D1 (de)	2009-01-02	Kassetteneinspannmechanismus
DE602007001280D1 (de)	2009-07-30	Getränkeextraktor
DK2144905T3 (da)	2013-03-11	Terapeutiske midler
DE602006020192D1 (de)	2011-03-31	Riemenscheibenanorndung
DE602007001098D1 (de)	2009-06-25	Spindelmäheinheit
DE502007001629D1 (de)	2009-11-12	Rfahren
ATE546437T1 (de)	2012-03-15	Aminomethyl-4-imidazole
BRPI0720224A2 (pt)	2013-12-24	Arilpirazóis substituídos
DE502007000218D1 (de)	2008-12-18	nsetzungen
DE602007000501D1 (de)	2009-03-12	Breitbandrichtkoppler
DE502007002453D1 (de)	2010-02-11	Kunstoffverdichtergehäuse
DK2173831T3 (da)	2012-09-17	Brøndbehandling
DE502007000361D1 (de)	2009-02-26	Stanznieteinheit
DE602007000333D1 (de)	2009-01-22	Napfbefestigungsvorrichtung
BRPI0818598A2 (pt)	2017-05-16	agentes terapêuticos - 802
DE602006019150D1 (de)	2011-02-03	Riemenscheibenanorndung
BRPI0820410A2 (pt)	2015-05-19	Lactans substituídos terapêuticos
DE112007003147A5 (de)	2009-09-24	Rohr-Biegevorrichtung